Bone health in children and adolescents with steroid-sensitive nephrotic syndrome assessed by DXA and QUS

• DOI: 10.1007/s00467-014-2834-3
• Publication Date: 2014-06-06T00:45:10Z
• Authors: Gabriella Aceto; Olinda D’Addato; Giovanni Messina; Vincenza Carbone; Luciano Cavallo; Giacomina Brunetti; Maria Felicia Fai...
• Keywords: Male; 0303 health sciences; Nephrotic Syndrome; Adolescent; Puberty; Anti-Inflammatory Agents; Infant; Bone and Bones; 3. Good health; Bone status; Dual energy X-ray absorptiometry; Glucocorticoids; Quantitative ultrasonometry; Steroid-sensitive nephrotic syndrome; 03 medical and health sciences; Absorptiometry, Photon; Calcification, Physiologic; Child, Preschool; Humans; Osteoporosis; Female; Steroids; Child; Glucocorticoids; Ultrasonography

The management of steroid-sensitive nephrotic syndrome (SSNS) requires treatment with high-dose glucocorticoids (GCs), but GC usage causes the most frequent form of drug-induced osteoporosis. The aim of our study was to evaluate the impact of GCs on bone mineralization in patients with SSNS using two diagnostic tools, dual-energy X-ray densitometry (DXA) and quantitative ultrasound (QUS), and to compare the diagnostic efficacy of these two imaging tools.A total of 30 children with SSNS (age 5.20 ± 2.20 years) were evaluated at the start (T0) and after 1 (T1), 2.44 ± 0.75 (T2, 18 patients) and 5.96 ± 2.33 years (T4, 12 patients) of GC treatment. Patients who stopped at T2 were also evaluated at the 1-year timepoint after ceasing GC treatment (T3).Of the patients assessed at T2, 11 had bone mineralization at the lower limit of normal versus those at T0 and T1, with bone mineralization rescue at the 1-year timepoint after GC discontinuation. At T4, 6/12 patients had densitometric parameters at the lower limit of normal values, and 3/12 patients showed reduced bone mineralization. The parameters derived from measurements of DXA and QUS were significantly related to each timepoint.Patients with SSNS receiving GC therapy undergo bone status alteration related to the dosage and duration of the therapy. In terms of diagnostic efficacy, DXA and QUS were comparable, indicating that QUS is a reliable tool to evaluate bone health in children with SSNS.